Literature DB >> 35681044

Prevalence and clinical characteristics of primary aldosteronism in a tertiary-care center in Korea.

Minjae Yoon1,2, Namki Hong3, Jaehyung Ha1, Chan Joo Lee1, Cheol Ryong Ku3, Yumie Rhee4, Sungha Park5.   

Abstract

Approximately 29% of Korean adults have hypertension; however, the prevalence of primary aldosteronism among the hypertensive population is largely unknown. The aim of our study was to evaluate the prevalence and clinical characteristics of primary aldosteronism in a tertiary-care center in Korea. We retrospectively analyzed 1173 patients with newly diagnosed or preexisting hypertension who were referred to our tertiary-care hospital between January 2013 and December 2018. Patients were screened for primary aldosteronism with the aldosterone-renin ratio and underwent a saline infusion test for diagnostic confirmation. Adrenal computed tomography and adrenal venous sampling were performed for subtype classification for primary aldosteronism. Among the 1173 patients (mean age, 51.8 years; women, 53.2%), 360 (30.7%) had positive screening-test results, of whom 71 (6.1%) were finally diagnosed with primary aldosteronism. Conclusive subtype differentiation was made in 55 patients, of whom 15 (27%) had an aldosterone-producing adenoma, 4 (7%) had unilateral adrenal hyperplasia, and 36 (66%) had bilateral adrenal hyperplasia. Patients with primary aldosteronism had a higher ambulatory blood pressure, left ventricular mass index, and urinary albumin-to-creatinine ratio than those without. Moreover, the primary aldosteronism group had a higher prevalence of left ventricular hypertrophy and albuminuria than the non-primary aldosteronism group. Primary aldosteronism may be more common (6.1%) among Korean patients with hypertension than generally recognized. Primary aldosteronism was associated with a higher degree and prevalence of target organ damage and a higher blood pressure level. Wide application of screening tests for primary aldosteronism may be beneficial in detecting this potentially curable cause of hypertension.
© 2022. The Author(s), under exclusive licence to The Japanese Society of Hypertension.

Entities:  

Keywords:  Ambulatory blood pressure monitoring; Hypertension; Primary aldosteronism; Target-organ damage

Mesh:

Substances:

Year:  2022        PMID: 35681044     DOI: 10.1038/s41440-022-00948-7

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   5.528


  39 in total

1.  Incidence of primary aldosteronism uncomplicated "essential" hypertension. A prospective study with elevated aldosterone secretion and suppressed plasma renin activity used as diagnostic criteria.

Authors:  L M Fishman; O Küchel; G W Liddle; A M Michelakis; R D Gordon; W T Chick
Journal:  JAMA       Date:  1968-08-12       Impact factor: 56.272

2.  Long-term cardio- and cerebrovascular events in patients with primary aldosteronism.

Authors:  Paolo Mulatero; Silvia Monticone; Chiara Bertello; Andrea Viola; Davide Tizzani; Andrea Iannaccone; Valentina Crudo; Jacopo Burrello; Alberto Milan; Franco Rabbia; Franco Veglio
Journal:  J Clin Endocrinol Metab       Date:  2013-09-20       Impact factor: 5.958

Review 3.  Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis.

Authors:  Silvia Monticone; Fabrizio D'Ascenzo; Claudio Moretti; Tracy Ann Williams; Franco Veglio; Fiorenzo Gaita; Paolo Mulatero
Journal:  Lancet Diabetes Endocrinol       Date:  2017-11-09       Impact factor: 32.069

4.  Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism.

Authors:  Paul Milliez; Xavier Girerd; Pierre-François Plouin; Jacques Blacher; Michel E Safar; Jean-Jacques Mourad
Journal:  J Am Coll Cardiol       Date:  2005-04-19       Impact factor: 24.094

5.  Hypokalemia in the hypertensive patient, with observations on the incidence of primary aldosteronism.

Authors:  N M Kaplan
Journal:  Ann Intern Med       Date:  1967-06       Impact factor: 25.391

6.  Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents.

Authors:  Paolo Mulatero; Michael Stowasser; Keh-Chuan Loh; Carlos E Fardella; Richard D Gordon; Lorena Mosso; Celso E Gomez-Sanchez; Franco Veglio; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2004-03       Impact factor: 5.958

7.  The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline.

Authors:  John W Funder; Robert M Carey; Franco Mantero; M Hassan Murad; Martin Reincke; Hirotaka Shibata; Michael Stowasser; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2016-03-02       Impact factor: 5.958

8.  Cardiovascular outcomes in patients with primary aldosteronism after treatment.

Authors:  Cristiana Catena; GianLuca Colussi; Elisa Nadalini; Alessandra Chiuch; Sara Baroselli; Roberta Lapenna; Leonardo A Sechi
Journal:  Arch Intern Med       Date:  2008-01-14

9.  The incidence rate of phaeochromocytoma and Conn's syndrome in Denmark, 1977-1981.

Authors:  G S Andersen; D B Toftdahl; J O Lund; S Strandgaard; P E Nielsen
Journal:  J Hum Hypertens       Date:  1988-10       Impact factor: 3.012

10.  Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism.

Authors:  Gian Paolo Rossi; Maurizio Cesari; Cesare Cuspidi; Giuseppe Maiolino; Maria Verena Cicala; Valeria Bisogni; Franco Mantero; Achille C Pessina
Journal:  Hypertension       Date:  2013-05-06       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.